Influence of intravenous pirenzepine on gastric acid and pepsin in man.
Patients with dyspepsia were asked to volunteer for two gastric secretion tests preceded by a single intravenous injection of pirenzepine 10 mg in the one and 0.9% saline in the other (in random order). In each test gastric secretion was aspirated continuously. 0.9% saline was infused intravenously for 30 minutes followed by insulin 0.15 micrograms/kg-h for 90 minutes, saline for 30 minutes and finally pentagastrin for 90 minutes in doses of either 6, 1, 0.5 or 0.25 micrograms/kg-h. Gastric samples were analysed for volume, pH, titratable acidity and pepsin. Basal outputs of acid and pepsin were not altered by pirenzepine. Insulin-stimulated acid output was significantly reduced (p less than 0.05) from a mean of 32.7 to 22.6 mmol/h (-31%). The mean percentage reduction was 16%. Acid and pepsin outputs after pentagastrin 0.25-6 micrograms/kg-h were not significantly altered by this dose of pirenzepine.
D000328:Adult; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism*; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D010890:Pirenzepine
D001570:Benzodiazepinones; D007328:Insulin; D010879:Piperazines; D010890:Pirenzepine; D010434:Pepsin A; D010418:Pentagastrin